AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

HEADQUARTERS IN ROCKVILLE. THIS LAB ISN’T OPEN OR OPERATIONAL YET, BUT ONCE IT IS, THE FOLKS AT ASTRAZENECA BELIEVE IT IS GOING TO REVOLUTIONIZE CANCER TREATMENT. IT GIVES US HOPE. I MEAN.

State officials and AstraZeneca marked the opening Monday of a cell therapy facility in Rockville that aims to create pathways to jobs for the state’s STEM professionals. AstraZeneca completed a ...

pharmaphorum speaks with Steven Davis of AstraZeneca on how the first year of its first direct-to-patient program - ARIMIDEX Direct has been. A year ago, AstraZeneca announced its first direct-to ...

The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3.5 billion there by the end of 2026. Soriot said earlier in the year that he ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

A cyclist has died following a road collision in Coolock in Dublin. The collision, which involved a car, occurred on the R139 in Dublin 17, shortly after 8pm yesterday evening. The cyclist ...

But private sector companies like AstraZeneca are pushing forward with major investments in life sciences research and manufacturing. The Cambridge, U.K.-based pharmaceutical giant on Monday ...

AstraZeneca and Honeywell are developing MDIs that will use a new propellant called HFO-1234ze, which, according to the company, has 99.9% less Global Warming Potential (GWP) than existing ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

Positive high-level results from the phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination ...